Vectura's VR040 meets Parkinson's endpoint

Vectura Group plc (LSE:VEC) said VR040 met the primary endpoint of significantly improving Unified Parkinson's Disease Rating Scale (UPDRS) Part III scores from baseline vs. placebo in a Phase II tria...